Mercer Global Advisors
RNAZ icon

Mercer Global Advisors’s TransCode Therapeutics RNAZ Stock Holding History

Mercer Global Advisors’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.53K Buy
+1,535
New +$10.4K ﹤0.01% 5151

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Mercer Global Advisors's RNAZ Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in TransCode Therapeutics (RNAZ) in Q2 2026: 1,535 shares worth $9.53K. The stake represents ﹤0.01% of the portfolio and ranks #5151 among its holdings.

7 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Mercer Global Advisors held 1,535 shares of TransCode Therapeutics worth $9.53K as of Q2 2026.
  • TransCode Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • TransCode Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5151 holding.
  • 7 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.